FLAG regimen: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 3: Line 3:
{{CMG}}; {{AE}} {{AV}}
{{CMG}}; {{AE}} {{AV}}


==Overview==


==Overview==
{{PAGENAME}} refers to a regimen consisting of [[fludarabine]], high-dose [[cytarabine|cytarabine (AraC)]] and [[filgrastim]] ([[G-CSF]]), used as a remission-induction treatment for relapsed or refractory childhood [[acute myeloid leukemia]] (AML)<ref name="pmid9625576">{{cite journal| author=Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A et al.| title=Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. | journal=Am J Hematol | year= 1998 | volume= 58 | issue= 2 | pages= 105-9 | pmid=9625576 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9625576 }} </ref>
{{PAGENAME}} refers to a regimen consisting of [[fludarabine]], high-dose [[cytarabine|cytarabine (AraC)]] and [[filgrastim]] ([[G-CSF]]), used as a remission-induction treatment for relapsed or refractory childhood [[acute myeloid leukemia]] (AML)<ref name="pmid9625576">{{cite journal| author=Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A et al.| title=Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. | journal=Am J Hematol | year= 1998 | volume= 58 | issue= 2 | pages= 105-9 | pmid=9625576 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9625576 }} </ref>



Latest revision as of 20:16, 17 March 2015

WikiDoc Resources for FLAG regimen

Articles

Most recent articles on FLAG regimen

Most cited articles on FLAG regimen

Review articles on FLAG regimen

Articles on FLAG regimen in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on FLAG regimen

Images of FLAG regimen

Photos of FLAG regimen

Podcasts & MP3s on FLAG regimen

Videos on FLAG regimen

Evidence Based Medicine

Cochrane Collaboration on FLAG regimen

Bandolier on FLAG regimen

TRIP on FLAG regimen

Clinical Trials

Ongoing Trials on FLAG regimen at Clinical Trials.gov

Trial results on FLAG regimen

Clinical Trials on FLAG regimen at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on FLAG regimen

NICE Guidance on FLAG regimen

NHS PRODIGY Guidance

FDA on FLAG regimen

CDC on FLAG regimen

Books

Books on FLAG regimen

News

FLAG regimen in the news

Be alerted to news on FLAG regimen

News trends on FLAG regimen

Commentary

Blogs on FLAG regimen

Definitions

Definitions of FLAG regimen

Patient Resources / Community

Patient resources on FLAG regimen

Discussion groups on FLAG regimen

Patient Handouts on FLAG regimen

Directions to Hospitals Treating FLAG regimen

Risk calculators and risk factors for FLAG regimen

Healthcare Provider Resources

Symptoms of FLAG regimen

Causes & Risk Factors for FLAG regimen

Diagnostic studies for FLAG regimen

Treatment of FLAG regimen

Continuing Medical Education (CME)

CME Programs on FLAG regimen

International

FLAG regimen en Espanol

FLAG regimen en Francais

Business

FLAG regimen in the Marketplace

Patents on FLAG regimen

Experimental / Informatics

List of terms related to FLAG regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Overview

FLAG regimen refers to a regimen consisting of fludarabine, high-dose cytarabine (AraC) and filgrastim (G-CSF), used as a remission-induction treatment for relapsed or refractory childhood acute myeloid leukemia (AML)[1]

Regimen

FLFludarabine

ACytarabine (AraC)

GFilgrastim (G-CSF)

Indications

References

  1. 1.0 1.1 Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A; et al. (1998). "Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia". Am J Hematol. 58 (2): 105–9. PMID 9625576.